Kras基因突变的非小细胞肺癌靶向治疗进展

Target therapy of Kras mutant on non-small cell lung cancer

肺癌占恶性肿瘤死因的第一位,其中非小细胞肺癌(NSCLC)占绝大多数。已发现三分之一的NSCLC和Kras基因突变直接相关,故针对Kras突变的靶向治疗是近年来肺癌研究的热点。本文从抑制Kras膜定位、直接抑制Kras、抑制其下游信号和抑制Kras突变的协同致死因子四个方面对目前的研究进展做一简要概论。

Lung cancer is the leading cause of malignant tumors,of which most of the cases are non - small cell lung cancer（NSCLC）. It has been demonstrated that Kras gene mutation has direct association with one third of lung canc-er cases,therefore these is a great need for new target therapeutic strategies for this disease. Here we review,in the context of NSCLC,the novel target therapies to inhibit four aspects of mutant Kras protein,i. e. membrane association, enzymatic activity,downstream signaling and synthetic lethal targets.